Helixon develops an AI scientific-computing platform combined with in-house high-throughput biological experiment capabilities to provide molecular computation, simulation and design tools for drug developers. The company focuses particularly on large-molecule drug discovery and immunotherapies, developing machine-learning algorithms and data-acquisition technologies to rework drug-development workflows. It has created multiple protein-design and modelling algorithms and integrated them with high-throughput experimental platforms to complete AI-design / experimental-validation iterative loops. Helixon says it is building out multiple large-molecule and immunotherapy pipelines with plans to advance them toward the clinic. Since its founding in June 2021, the company has recruited leading domestic and international experts in AI research, structural biology and disease research. The business has attracted market recognition and has just completed a significant Series A financing to support expansion.

Total raised

$75M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2022